Compare TACT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | XLO |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 41.8M |
| IPO Year | 1996 | 2021 |
| Metric | TACT | XLO |
|---|---|---|
| Price | $4.13 | $0.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $2.00 |
| AVG Volume (30 Days) | 32.3K | ★ 411.9K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,258,000.00 | $31,804,000.00 |
| Revenue This Year | $21.67 | $626.78 |
| Revenue Next Year | $7.63 | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.27 | ★ 588.40 |
| 52 Week Low | $3.12 | $0.62 |
| 52 Week High | $5.70 | $1.70 |
| Indicator | TACT | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 48.18 |
| Support Level | $3.67 | $0.63 |
| Resistance Level | $4.07 | $0.74 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 67.69 | 46.87 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.